Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults

NCT02333591 is registered in ClinicalTrials.gov with Mette Zander as lead sponsor.

NCT NCT02333591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02333591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults
Lead sponsor
Mette Zander
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2016
Completion date
June 30, 2018
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary microvascular dysfunction